PBAC's latest decision on Ziprasidone hydrochloride: Recommended with restriction (2008). Considered for treatment of acute mania or mixed episodes associated with bipolar I disorder.
PBAC outcome
Recommended with restriction
Authority Required (STEAMLINED)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2006
Submissions
3
2006 → 2008
Eligible population
adults with acute mania or mixed episodes associated with bipolar I disorder
Therapy area
Mental health
Line of therapy
Not applicable
Evidence base
RCT, Meta-analysis
Primary endpoint
change from baseline in Young/Mania Rating Scale (Y/MRS) scores
Key trials
128-601, A1281083, A1281052, Tohen et al (1999), Tohen et al (2000), Tohen et al (2003)
Comparator
olanzapine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated
Submission history
Nov 2006: Recommended with restriction · Authority Required
Nov 2008: Recommended with restriction · Authority Required
Nov 2008: Recommended with restriction · Authority Required (STEAMLINED)